VANGUARD GROUP INC 13D and 13G filings for Ligand Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:08 pm Purchase | 2023-12-29 | 13G | Ligand Pharmaceuticals Incorporated LGND | VANGUARD GROUP INC | 1,876,514 10.760% | 33,399 (+1.81%) | Filing |
| 2023-02-09 11:25 am Sale | 2022-12-30 | 13G | Ligand Pharmaceuticals Incorporated LGND | VANGUARD GROUP INC | 1,843,115 10.910% | -908,811 (-33.02%) | Filing |
| 2022-02-10 08:22 am Sale | 2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | VANGUARD GROUP INC | 2,751,926 10.270% | -8,906 (-0.32%) | Filing |
| 2021-10-12 09:29 am Purchase | 2021-09-30 | 13G | Ligand Pharmaceuticals Incorporated LGND | VANGUARD GROUP INC | 2,760,832 10.330% | 422,176 (+18.05%) | Filing |
| 2021-02-10 11:14 am Sale | 2020-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | VANGUARD GROUP INC | 2,338,657 9.070% | -178,074 (-7.08%) | Filing |